FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365514164> ?p ?o ?g. }

• W4365514164 endingPage "CT011" @default.
• W4365514164 startingPage "CT011" @default.
• W4365514164 abstract "Abstract Background: While doublet therapies provide important first-line treatment options in metastatic renal cell carcinoma (mRCC), novel and mechanistically distinct agents are needed for pts who are not cured by/intolerant of such therapies. Due to the high incidence (~80%) of CD70 antigen expression in primary and mRCC, yet limited expression in normal tissue, ccRCC is an attractive proof-of-concept tumor for CD70 directed allogeneic CAR T. TRAVERSE (NCT04696731), a first-in-human trial, seeks to identify a maximum tolerated dose (MTD) of ALLO-316 after conditioning with fludarabine/cyclophosphamide with/without ALLO-647 in pts with advanced or metastatic ccRCC. ALLO-316 is an anti-CD70 allogeneic CAR T cell product that utilizes TALEN® gene editing to knock out TCRα constant gene to reduce the risk of graft-versus-host disease (GvHD) and knock out CD52 gene to permit use of ALLO-647 (a humanized anti-CD52 mAb) to selectively deplete host T cells without affecting allogeneic CAR T cells. Methods: This multicenter, single-arm, open-label, 3+3 dose-escalation trial enrolls adults with advanced or metastatic ccRCC and ≥1 measurable lesion and ECOG Performance Status 0 or 1. Prior treatment with an immune checkpoint inhibitor and a vascular endothelial growth-factor targeted therapy was required, with evidence of progression on/after treatment or discontinuation due to toxicity. ALLO-316 is administered at escalating doses (40 - 240 × 106 allogeneic CAR+ cells IV) on Day 0 after conditioning. The primary endpoint is a target incidence rate for dose-limiting toxicities (DLTs) &lt;33% in the first 28 days after infusion of ALLO-316. Results: By 12/3/2022, 18 pts with ccRCC (median age: 63 yrs; 82% male) were enrolled; all (100%) 17 pts who received ALLO-316, had metastatic disease with 3 lines (median) of prior therapy. Eleven (65%) of these pts experienced CRS, all low Gr except one (6%) Gr 3. No ICANS or GVHD was observed. One (6%) DLT (elevated LFT) was observed and required dose expansion. MTD has not yet been reached. Three pts achieved best overall response of PR at all time points with two PRs confirmed at subsequent visits; ORR = 12% and disease control rate (DCR) = 71%. In pts with confirmed CD70+ tumors (n=9), confirmed ORR = 22% (unconfirmed ORR = 33%) and DCR = 100%. High CAR T cell expansion was observed in peripheral blood (median Cmax &gt; 35,000 copies/μg) and high VCN in available tumor aspirates (n=3). Conclusions: ALLO-316, an allogeneic CAR T cell product targeting CD70 in advanced mRCC, is demonstrating encouraging antitumor activity and a manageable safety profile. A single administration of ALLO-316 could be an effective treatment for pts with CD70+ solid tumors, including RCC, and hematologic malignancies. The MTD for ALLO-316 in TRAVERSE will support Phase 2 trial design. Enrollment of pts with CD70+ tumors is ongoing. Citation Format: Samer Srour, Ritesh Kotecha, Brendan Curti, Jad Chahoud, Alexandra Drakaki, Lily Tang, Lovely Goyal, Sacha Prashad, Victoria Szenes, Kevin Norwood, Sumanta Pal. A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT011." @default.
• W4365514164 created "2023-04-15" @default.
• W4365514164 creator A5000199866 @default.
• W4365514164 creator A5013868136 @default.
• W4365514164 creator A5014154182 @default.
• W4365514164 creator A5014230214 @default.
• W4365514164 creator A5019538697 @default.
• W4365514164 creator A5029588412 @default.
• W4365514164 creator A5033795704 @default.
• W4365514164 creator A5038619722 @default.
• W4365514164 creator A5053725787 @default.
• W4365514164 creator A5066618983 @default.
• W4365514164 creator A5070032327 @default.
• W4365514164 date "2023-04-14" @default.
• W4365514164 modified "2023-09-23" @default.
• W4365514164 title "Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)" @default.
• W4365514164 doi "https://doi.org/10.1158/1538-7445.am2023-ct011" @default.
• W4365514164 hasPublicationYear "2023" @default.
• W4365514164 type Work @default.
• W4365514164 citedByCount "0" @default.
• W4365514164 crossrefType "journal-article" @default.
• W4365514164 hasAuthorship W4365514164A5000199866 @default.
• W4365514164 hasAuthorship W4365514164A5013868136 @default.
• W4365514164 hasAuthorship W4365514164A5014154182 @default.
• W4365514164 hasAuthorship W4365514164A5014230214 @default.
• W4365514164 hasAuthorship W4365514164A5019538697 @default.
• W4365514164 hasAuthorship W4365514164A5029588412 @default.
• W4365514164 hasAuthorship W4365514164A5033795704 @default.
• W4365514164 hasAuthorship W4365514164A5038619722 @default.
• W4365514164 hasAuthorship W4365514164A5053725787 @default.
• W4365514164 hasAuthorship W4365514164A5066618983 @default.
• W4365514164 hasAuthorship W4365514164A5070032327 @default.
• W4365514164 hasConcept C126322002 @default.
• W4365514164 hasConcept C143998085 @default.
• W4365514164 hasConcept C203092338 @default.
• W4365514164 hasConcept C2777472916 @default.
• W4365514164 hasConcept C2778384904 @default.
• W4365514164 hasConcept C2779015954 @default.
• W4365514164 hasConcept C2781278892 @default.
• W4365514164 hasConcept C2911091166 @default.
• W4365514164 hasConcept C535046627 @default.
• W4365514164 hasConcept C71924100 @default.
• W4365514164 hasConceptScore W4365514164C126322002 @default.
• W4365514164 hasConceptScore W4365514164C143998085 @default.
• W4365514164 hasConceptScore W4365514164C203092338 @default.
• W4365514164 hasConceptScore W4365514164C2777472916 @default.
• W4365514164 hasConceptScore W4365514164C2778384904 @default.
• W4365514164 hasConceptScore W4365514164C2779015954 @default.
• W4365514164 hasConceptScore W4365514164C2781278892 @default.
• W4365514164 hasConceptScore W4365514164C2911091166 @default.
• W4365514164 hasConceptScore W4365514164C535046627 @default.
• W4365514164 hasConceptScore W4365514164C71924100 @default.
• W4365514164 hasIssue "8_Supplement" @default.
• W4365514164 hasLocation W43655141641 @default.
• W4365514164 hasOpenAccess W4365514164 @default.
• W4365514164 hasPrimaryLocation W43655141641 @default.
• W4365514164 hasRelatedWork W1755290823 @default.
• W4365514164 hasRelatedWork W2085356529 @default.
• W4365514164 hasRelatedWork W2144031118 @default.
• W4365514164 hasRelatedWork W2283641106 @default.
• W4365514164 hasRelatedWork W2590066672 @default.
• W4365514164 hasRelatedWork W2767323531 @default.
• W4365514164 hasRelatedWork W2972396084 @default.
• W4365514164 hasRelatedWork W3210028029 @default.
• W4365514164 hasRelatedWork W4210571220 @default.
• W4365514164 hasRelatedWork W4220838179 @default.
• W4365514164 hasVolume "83" @default.
• W4365514164 isParatext "false" @default.
• W4365514164 isRetracted "false" @default.
• W4365514164 workType "article" @default.